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Background: Antiretroviral therapy reduces mother-to-child transmission of human immunodeficiency virus (HIV)
during pregnancy, delivery, and breastfeeding. However, these agents have been associated with preterm birth,
anemia and low birth weight. We aim to evaluate the comparative safety and effectiveness of the use of antiretroviral
drugs among HIV-infected women and the effects on their infants and children through a systematic review and
network meta-analysis.
Methods/Design: Studies examining the effects of six antiretroviral drug classes (nucleoside reverse transcriptase
inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors,
co-receptor inhibitors) administered to HIV-infected pregnant women will be included. We will include randomized clinical
trials (RCTs), quasi-RCTs, non-RCTs, controlled before-after, interrupted time series, cohort, registry, and case–control studies.
No limitations will be imposed on publication status (that is, unpublished studies are eligible for inclusion), duration of
follow-up, study conduct period, and language of dissemination. Comprehensive literature searches will be conducted in
major electronic databases, including MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. Gray
literature will be identified through searching dissertation databases, trial protocol registries, and conference abstracts.
Two team members will independently screen all citations, full-text articles, and abstract data; conflicts will be resolved
through discussion. The risk of bias and methodological quality will be appraised using appropriate tools (for example,
Cochrane Collaboration’s tool for assessing risk of bias, Newcastle-Ottawa Scale, and McMaster Quality Assessment Scale
of Harms). If feasible and appropriate, we will conduct random effects meta-analysis. Network meta-analysis will be
considered for outcomes with the greatest number of treatment comparisons available that fulfill network meta-analysis
assumptions (for example, consistency of evidence between direct and indirect data, and low statistical heterogeneity
between included studies).
The primary effectiveness outcome is mother-to-child transmission of HIV, and the primary safety outcome is major
congenital malformation (overall and specific types) among newborns of HIV-infected women. Secondary safety
outcomes include stillbirths, infant/child death, preterm delivery, overall and specific minor congenital malformations,
and small for gestational age infants.
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Discussion: Our systematic review will be of utility to healthcare providers, policy-makers, and HIV-positive women re-
garding the use of antiretroviral drugs.
Trial registration: PROSPERO registry number: CRD42014009071.
Keywords: antiretroviral therapy, breastfeeding, congenital malformation, human immunodeficiency virus, fetus,
mother-to-child-transmission, pregnancyBackground
In 2008, more than 2.1 million children aged 15 years and
younger were infected with human immunodeficiency virus
(HIV) worldwide [1]. The majority of these cases were pre-
ventable [1]. Mother-to-child transmission of HIV in-utero
and during delivery account for a large proportion of HIV
infections among children born to women not being
treated for HIV [2]. In addition, HIV infection can be ac-
quired through breastfeeding of children by women who
are not treated [3-5]. In fact, one randomized trial found
that up to 44% of infant HIV infections were due to breast-
feeding alone [6]. Other factors that increase the risk of
mother-to-child transmission of HIV include delivery
method (vaginal versus cesarean section), mother’s plasma
RNA viral load, and gestational age [7].
In developed countries, highly active antiretroviral ther-
apy (HAART) has reduced the mother-to-child HIV trans-
mission rate to approximately 1 to 2% [8]. However,
HAART is not available to many women living in low to
middle economy countries, where other treatment regi-
mens are routinely administered. For these women, sin-
gle antiretroviral therapy may be an effective option to
reduce mother-to-child transmission of HIV [9].
There are six major antiretroviral drug classes: 1) nu-
cleoside reverse transcriptase inhibitors (NRTIs), 2)
non-nucleoside reverse transcriptase inhibitors (non-
NRTIs), 3) protease inhibitors, 4) integrase inhibitors,
5) fusion inhibitor, and 6) co-receptor inhibitors (also
known as CCR5 antagonists) [2]. Each drug class has a
unique mechanism of action and safety profile. The
choice of medication regimen depends on the patient’s
clinical profile (for example, pregnancy and co-infection
with hepatitis B), potential adverse effects, complexity of
use, availability, cost, and patient preferences.
For women who are HIV-positive, naïve to antiretroviral
therapy, and pregnant, it is recommended that antiretro-
viral drugs are initiated after the first trimester of pregnancy
[2,10,11]. This is due to increased risk of major congenital
abnormalities, preterm delivery, anemia, and low birth
weight [2,8,12-17]. As such, our objective is to evaluate
the comparative safety and effectiveness of antiretroviral
drugs in HIV-infected pregnant women and their in-
fants who were exposed to HIV in-utero, during delivery
or while breastfeeding, through performance of a sys-
tematic review and network meta-analysis.Methods/Design
Protocol
A protocol was compiled for our systematic review and cir-
culated for feedback from the policy-makers who posed the
query within Health Canada, systematic review methodolo-
gists, clinicians, and pharmacologists. After completion, the
protocol was registered with the PROSPERO database
(CRD42014009071). The Preferred Reporting Items for Sys-
tematic reviews and Meta-analyses Protocols (or PRISMA-
P) was used to guide the reporting of this protocol [18].
Eligibility criteria
Only studies fulfilling our eligibility criteria will be in-
cluded [19], as outlined in Additional file 1:
1. Patients: Pregnant women infected with HIV-1 and/
or the fetuses and infants of mothers who are HIV-
positive. Studies of women infected with HIV-2 will
be excluded. Women at any stage of pregnancy will
be eligible for inclusion. Infants and children ex-
posed in-utero, during delivery or breastfeeding are
eligible for inclusion until 18 months of age or until
breastfeeding is discontinued. All countries and set-
tings are eligible for inclusion.
2. Interventions: Any of the 24 antiretroviral
medications approved for use in Canada from the
aforementioned classes, as presented in Additional
file 2 [20]. We will include studies of all
combinations and doses of these medications. In
order to be included, the antiretroviral medication
must be administered to HIV-infected pregnant
women; we will not include studies examining anti-
retroviral treatment directly administered to infants
or children.
3. Comparators: Antiretroviral medications against
each other, against placebo/no treatment, or
combinations of two or more antiretroviral drugs.
4. Outcomes: The primary effectiveness outcome is
mother-to-child transmission of HIV, which is de-
fined as infant HIV-infection from 2 weeks of age to
18 months or until breastfeeding is discontinued.
The primary safety outcome is major congenital
malformations (overall and by specific type), which
is defined as a malformation present from birth that
requires substantial medical intervention, including
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stillbirths, infant/child death (up to 18 months of
age), minor congenital malformations (overall and
by specific types), small for gestational age infants
(defined as weight below the 10th percentile for
gestational age), and preterm delivery,
5. Study designs: Experimental (randomized clinical
trials (RCTs), quasi-RCTs, and non-RCTs), quasi-
experimental (controlled before and after studies and
interrupted time series) and observational (cohort,
case control, and registry studies) studies.
6. Other limitations: No limitations will be imposed on
publication status, language of dissemination, duration
of study follow-up or period of study conduct.
Information sources and literature search
The primary source of literature will be a structured
search of major electronic databases, including MED-
LINE, EMBASE, and the Cochrane Central Register of
Controlled Trials. The secondary source of potentially
relevant material will be a search of the gray literature
[21], including dissertation databases (ProQuest Disserta-
tions and Theses Database), clinical trial registries (for ex-
ample, World Health Organization International Clinical
Trials Search Portal), and conference abstracts from se-
lected international symposia on HIV. Literature satu-
ration will be achieved by contacting antiretroviral drug
manufacturers, scanning the reference lists of included
studies and relevant reviews, and contacting authors who
are prolific in HIV research.
The literature searches will be conducted by an expe-
rienced librarian. Our main (MEDLINE) literature
search was peer-reviewed by a different librarian using the
Peer Review of Electronic Search Strategies (PRESS)
checklist [22]. The final MEDLINE search is provided
in Additional file 3.
Study selection process
Our draft eligibility form is presented in Additional file 1,
which will be used for screening titles and abstracts (or
citations) and potentially relevant full-text articles. The
eligibility form will be revised, as necessary, during a
calibration exercise with the team. Full screening will
only occur when high agreement (for example, kappa
statistic ≥60%) [23] is observed across the team. Subse-
quently, two team members will screen each citation
and potentially relevant full-text article independently
using our online screening software (synthesi.sr) [24].
Conflicts will be resolved through discussion until con-
sensus is achieved.
Data items and data collection process
Data will be abstracted for the following factors:1. Study characteristics: study design, year of conduct,
duration of follow-up, sample size, setting, country
of study conduct, and type of antiretroviral drugs
examined.
2. Patient characteristics: mean age of the mother and
infant/child, gestational stage when antiretroviral
medication administered, family history of
congenital malformations, breastfeeding, maternal
HIV viral load, maternal CD4 count, history of other
sexually transmitted diseases, chorioamnionitis,
prolonged rupture of membranes, mode of delivery,
postpartum or intrapartum hemorrhage, history of
previous stillbirth, consumption of folate, tobacco
and alcohol during pregnancy.
3. Outcome results at the longest duration of follow-up
(for example, congenital malformations, and infant/
child mortality).
A standardized data abstraction tool will be developed
in excel and calibrated with the team. Subsequently, each
of the included studies will be abstracted by two team
members, independently, and conflicts will be resolved
through discussion. During this stage, duplicate publica-
tions (or companion reports) will be sorted [25], and au-
thors will be contacted for data clarifications, as necessary.
Methodological quality/risk of bias appraisal
The risk of bias of experimental and quasi-experimental
studies will be appraised using the Cochrane Effective
Practice and Organization of Care tool for assessing risk
of bias [26]. The methodological quality of observational
studies will be appraised using the Newcastle-Ottawa
Scale [27]. Publication bias will be assessed using funnel
plots [28]. Finally, studies reporting harms will be appraised
using the McHarm tool [29].
Synthesis of included studies
Fixed and random-effects meta-analysis will be conducted
[30,31] separately for studies including patients receiving
single or combinations of antiretroviral medications for
RCTs. Summary estimates will be displayed along with
their 95% confidence intervals (CI). Differences between
fixed and random effects estimates suggest that there are
differences between the estimated treatment effects of
small and large studies [32]. Such differences will be ex-
amined using funnel plots and Harbord’s test for funnel
plot asymmetry [33]. Funnel plots will be drawn when ten
or more studies are included in the meta-analysis. Asym-
metry will be explored by examining the study, clinical,
and methodological characteristics of the outlier studies.
As we anticipate that most studies will be retrospect-
ive, pooled odds ratios will be calculated for the relevant
outcomes, which are all dichotomous. For outcomes in
which studies reported 0 events in one treatment arm,
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to the denominator. Studies reporting 0 events in all
treatment arms for a particular outcome will be ex-
cluded from all analyses [34,35]. The placebo group will
be the reference for the first meta-analysis and the net-
work meta-analysis.
Statistical, clinical, and methodological heterogeneity
will be examined prior to conducting meta-analysis. We
will estimate the magnitude of statistical heterogeneity
using the restricted maximum likelihood and the Q-
profile method to estimate the 95% CI [36]. The propor-
tion of variability that is due to heterogeneity rather than
sampling error will also be quantified using the I2 measure
[37]. If extensive statistical (for example, I2 ≥ 75%), clinical,
or methodological heterogeneity [38] is observed, we will
conduct meta-regression analysis. The total number of co-
variates examined in meta-regression will be constrained
so that it is equal to 1/10 the number of studies [39].
Meta-regression analysis will explore the influence of
important factors such as baseline effect sizes (source of
statistical heterogeneity), gestational age when anti-
retroviral therapy was commenced and country/setting
of study conduct (sources of clinical heterogeneity), and
study quality (source of methodological heterogeneity)
on the meta-analysis results. Both meta-analysis and
meta-regression will be performed using the R software
with the metafor package [40]. Missing measures of
variance (for example, standard deviations and standard
errors) will be imputed using established methods [41].
Sensitivity analysis will be conducted to ensure our im-
putations for missing data do not bias our results [42].
A random-effects network meta-analysis will be con-
ducted to combine the different sources of evidence across
a network of studies and make inferences regarding the
relative effectiveness of multiple interventions [43]. Net-
work meta-analysis will only be considered for outcomes
with data on the majority of treatment comparisons,
which will be examined using network diagrams. We will
present the network diagrams for all outcomes to evaluate
the extent to which treatments are connected. The choice
of treatment nodes will be decided upon through discus-
sions with the clinicians, methodologists, and statisticians
from the team. For example, we will decide whether we
will conduct a class-level versus individual drug analysis,
incorporate standard/low/high dosages, and/or examine
timing of administration; these decisions will be informed
by a previous review of antiretroviral therapy [44].
A common estimate for the heterogeneity parameter
across comparisons will be assumed and its magnitude
will be judged according to the empirical heterogeneity
distribution [45]. The network meta-analysis results will
be presented as summary treatment effects (that is, mean
difference for continuous data and odds ratios for dichot-
omous data) for each pair of treatments. We will performnetwork meta-analysis employing the methodology of
multivariate meta-analysis in Stata using the mvmeta
command [46].
Prior to embarking on network meta-analysis, we will
ensure that the transitivity assumption is fulfilled, that
is, the distribution of the effect modifiers is comparable
across treatment comparisons [47]. For each outcome
we will construct a table of important patient character-
istics and draw boxplots to visually inspect the distribu-
tion (for example, age) or percentages (for example,
male/female) of factors we consider as potential modi-
fiers of the treatment effect. Lack of transitivity in a net-
work can create statistical disagreement between direct
and indirect evidence, that is, inconsistency [43,48].
Consistency between direct and indirect data will be ex-
amined locally, that is, in certain paths of the network,
using the loop-specific method [49,50] and the separat-
ing indirect and direct evidence (SIDE) method [51], and
globally, that is, evaluating the network as a whole, using
the design-by-treatment interaction model (DBT) [52]. If
we observe important heterogeneity and/or inconsist-
ency, we will explore the possible sources, such as effect
modifiers, as described above.
One advantage of a network meta-analysis is that it al-
lows the ranking of the safety and effectiveness of all
treatments examined. This will be conducted using ‘ran-
kograms’, as well as the surface under the cumulative
ranking curve (SUCRA) [53]. A sequential approach will
be used for the network meta-analysis, first restricted to
RCTs (which will be considered the primary analysis that
we will base our conclusions on), second adding quasi-
experimental data, and then finally incorporating data
from observational studies. Such analyses will allow the
determination of the contribution of non-randomized
studies to the findings from RCTs.
Discussion
Globally, more than 2 million children under the age of 15
years are infected by HIV. Most children acquire HIV
from mother-to-child transmission and many of these
cases are preventable. Effective antiretroviral therapy is
available, yet safety concerns during pregnancy have been
raised, including major congenital abnormalities, preterm
delivery, anemia, and low birth weight [8,12-17]. Our find-
ings regarding the comparative safety and effectiveness of
these agents will be of great importance to policy-makers,
healthcare providers, and patients. We are not aware of
another systematic review including a network meta-
analysis addressing this specific issue.
Numerous knowledge translation strategies will be used
to ensure our results have a broad reach. For example, our
proposal is an integrated knowledge translation whereby
researchers work jointly with end-users (in this case,
Health Canada, a regulatory agency). End-of-project
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cluding publication in peer-reviewed open access journals,
conferences, dissemination meetings, policy briefs and
social media.
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